SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
about
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile InfectionA Review of Experimental and Off-Label Therapies for Clostridium difficile InfectionEfficacy and safety of ridinilazole compared with vancomycin for the treatment of Clostridium difficile infection: a phase 2, randomised, double-blind, active-controlled, non-inferiority study.A randomised phase 1 study to investigate safety, pharmacokinetics and impact on gut microbiota following single and multiple oral doses in healthy male subjects of SMT19969, a novel agent for Clostridium difficile infections.DNA replication proteins as potential targets for antimicrobials in drug-resistant bacterial pathogens.Impact on toxin production and cell morphology in Clostridium difficile by ridinilazole (SMT19969), a novel treatment for C. difficile infection.MiniBioReactor Arrays (MBRAs) as a Tool for Studying C. difficile Physiology in the Presence of a Complex Community.New antibiotics in clinical trials for Clostridium difficile.In vitro susceptibility of Clostridium difficile to SMT19969 and comparators, as well as the killing kinetics and post-antibiotic effects of SMT19969 and comparators against C. difficileEnhanced preservation of the human intestinal microbiota by ridinilazole, a novel Clostridium difficile-targeting antibacterial, compared to vancomycin
P2860
Q28084026-72B9AE47-6E78-4517-AB85-0C65ED4C270FQ30240264-B1E424A0-3816-4D0B-8964-802CD756BBA5Q33831557-36C48E71-3F8A-4BB1-BB1D-DC73E2C9A64AQ35146382-BD907322-BF05-4BD9-A907-BEF7285CDD60Q39078552-85295620-3549-451E-AA68-034824D0FC8FQ40130108-255363E0-B5F8-40AC-B9DA-B1EA546918ECQ40581998-C1CC7042-C5AE-4E2F-AD85-E72D25A5B445Q40615409-0A549E01-F63F-4321-A520-2D76E2FDD2BDQ41148829-2A0AA5B2-C7A9-4920-990B-920B48862A48Q58803847-3EA0CDCC-C526-4C22-9D96-1EB6C3FA2E55
P2860
SMT19969 as a treatment for Clostridium difficile infection: an assessment of antimicrobial activity using conventional susceptibility testing and an in vitro gut model
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en-gb
type
label
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en-gb
prefLabel
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en-gb
P2093
P2860
P356
P6366
P1154
2-s2.0-84928315839
P1476
SMT19969 as a treatment for Cl ...... ting and an in vitro gut model
@en
P2093
G S Crowther
M H Wilcox
S D Baines
S Todhunter
P2860
P304
P356
10.1093/JAC/DKU324
P407
P5530
P577
2014-09-03T00:00:00Z
P5875
P6179
1044462448
P6366
2106915625